Jeffrey Schriber, MD
Hematology & Oncology · Scottsdale, AZNPI 1851369821
Payments from drug & device makers
Across 737 payments — averaging $3665.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1.2M
- CSL Behring$589K
- E.r. Squibb & Sons, L.L.C.$113K
- Astellas Pharma Global Development$102K
- Seagen Inc.$98K
- Beigene USA, Inc.$97K
- plus $455K from 29 others
Across 3 payments — averaging $1561.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$3K
- CSL Behring$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 45 | $1,248,457 |
| CSL Behring | 77 | $588,819 |
| E.r. Squibb & Sons, L.L.C. | 71 | $112,559 |
| Astellas Pharma Global Development | 19 | $101,987 |
| Seagen Inc. | 96 | $98,138 |
| Beigene USA, Inc. | 70 | $97,023 |
| AstraZeneca | 61 | $71,375 |
| Pharmacyclics LLC, An Abbvie Company | 20 | $68,704 |
| Astellas Pharma US Inc | 34 | $48,034 |
| Jazz Pharmaceuticals Inc. | 33 | $34,089 |
| Sanofi | 26 | $29,979 |
| Bristol Myers Squibb | 45 | $27,997 |
| Stemline Therapeutics Inc. | 18 | $27,749 |
| Agios Pharmaceuticals, Inc. | 27 | $25,528 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $21,890 |
| Janssen Research & Development, LLC | 3 | $21,700 |
| ADC Therapeutics America, Inc. | 10 | $17,435 |
| Beone Medicines USA, Inc. | 5 | $11,423 |
| National Marrow Donor Program | 1 | $9,856 |
| Karyopharm Therapeutics Inc. | 6 | $8,100 |
| Janssen Scientific Affairs, LLC | 4 | $5,813 |
| Sanofi-aventis U.S. LLC | 3 | $5,154 |
| Gilead | 8 | $4,873 |
| Epizyme, Inc. | 5 | $4,100 |
| Servier Pharmaceuticals LLC | 2 | $3,319 |
| GSK | 2 | $3,274 |
| Ipsen Biopharmaceuticals, Inc | 2 | $2,310 |
| Johnson & Johnson | 7 | $1,332 |
| Incyte Corporation | 1 | $125 |
| Morphosys, US Inc. | 1 | $88 |
| Amgen | 4 | $86 |
| AbbVie | 4 | $83 |
| Pfizer | 4 | $76 |
| Merck | 4 | $63 |
| Secura Bio, Inc. | 1 | $23 |
How this compares
$2,701,564 in reported general payments places this provider in the 90th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Scottsdale
- Tanios Bekaii-SaabScottsdale$31.4M
- Yousef ZakhariaScottsdale$13M
- Parminder SinghScottsdale$9.7M
- Michael GordonScottsdale$9.2M
- Daniel AhnScottsdale$9.1M
- Saurabh ChhabraScottsdale$6.5M
- Mitesh BoradScottsdale$3.6M
- Peter BergsagelScottsdale$3.6M
- Cassandra MooreScottsdale$3.5M
- Alexander StewartScottsdale$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.